Astrana Health (ASTH) Scheduled to Post Quarterly Earnings on Thursday

Astrana Health (NASDAQ:ASTH) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Astrana Health to post earnings of $0.33 per share for the quarter. Astrana Health has set its FY24 guidance at $1.12-1.36 EPS and its FY 2024 guidance at 1.120-1.360 EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.01. The business had revenue of $486.30 million during the quarter, compared to analysts’ expectations of $440.68 million. Astrana Health had a return on equity of 10.71% and a net margin of 4.30%. The firm’s revenue was up 39.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.28 EPS. On average, analysts expect Astrana Health to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Astrana Health Stock Performance

ASTH opened at $54.02 on Tuesday. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.62. The stock’s 50 day moving average price is $54.93 and its two-hundred day moving average price is $47.10. The firm has a market capitalization of $2.65 billion, a P/E ratio of 37.71, a price-to-earnings-growth ratio of 2.08 and a beta of 1.24. Astrana Health has a 12-month low of $28.86 and a 12-month high of $63.20.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ASTH shares. Truist Financial upped their target price on shares of Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Stifel Nicolaus upped their price objective on shares of Astrana Health from $48.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Robert W. Baird lifted their target price on Astrana Health from $54.00 to $67.00 and gave the stock an “outperform” rating in a research report on Thursday, August 15th. BTIG Research upped their price target on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a report on Thursday, October 3rd. Finally, KeyCorp began coverage on Astrana Health in a report on Friday, October 11th. They set a “sector weight” rating on the stock. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Astrana Health has a consensus rating of “Buy” and a consensus price target of $62.00.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.